Shore Capital Reaffirms House Stock Rating for Oxford BioDynamics (LON:OBD)

Shore Capital reissued their house stock rating on shares of Oxford BioDynamics (LON:OBD) in a research report released on Thursday,Digital Look reports.

Oxford BioDynamics Stock Performance

Shares of Oxford BioDynamics stock opened at GBX 0.52 ($0.01) on Thursday. The stock’s fifty day moving average is GBX 0.62 and its two-hundred day moving average is GBX 1.81. The company has a market capitalization of £9.82 million, a PE ratio of -0.09 and a beta of 0.42. The company has a quick ratio of 2.80, a current ratio of 0.68 and a debt-to-equity ratio of 370.22. Oxford BioDynamics has a 52 week low of GBX 0.45 ($0.01) and a 52 week high of GBX 10.60 ($0.14).

Oxford BioDynamics (LON:OBD) last announced its quarterly earnings data on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) EPS for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.